Previous studies have highlighted the importance of scaffolding activity of LSD1 in diverse cancer types [29, 30, 53, 54] and confirmed our finding that the catalytic inhibition of LSD1 is insufficient as a therapeutic strategy in human ETP-ALL [29, 30, 55], which needs further study. This evidence concerns the gene KDM1A and acute lymphoblastic leukemia.